Rheumatoid Arthritis 公开
[search 0]
更多
Download the App!
show episodes
 
Rheumatoid arthritis is a chronic long term condition that principally attacks flexible joints, causing painful swelling, stiffness and fatigue. The risk of developing RA is associated with ageing but it also affects adults of working age and is three times more common in women. 56 year old Liz noticed her first symptoms in 1996, when her son was just 2 years old. In this collection, she shares her experiences of living with RA, from early symptoms to drug-controlled remission.
  continue reading
 
Artwork

1
Biologic Therapy In Rheumatoid Arthritis

rhnews@elsevier.com (Rheumatology News International)

Unsubscribe
Unsubscribe
每月
 
Biologic Therapy in Rheumatoid Arthritis: Pioneers in Research, is a monthly series of podcasts featuring interviews with today's giants in rheumatology sponsored by Schering-Plough Corporation. In this series brought to you by Rheumatology News International, you will hear some of the greatest scientists in rheumatology describe the exploration of what was then uncharted medical territory. Their words will bring alive the journey of discovery that placed them in the annals of history's grea ...
  continue reading
 
Loading …
show series
 
This sixth podcast program, Individualizing Therapy: Today’s Options, Tomorrow’s Opportunities, features an interview with Professor McInnes. He discusses the current state of knowledge in rheumatoid arthritis and directions for discovery in coming years.由rhnews@elsevier.com (Rheumatology News International)
  continue reading
 
This fifth podcast titled Progress and Prognosis: Evaluating Patients’ Responses to Biologic Therapy features a telephone interview with Professor Schett. He discusses differences among the anti-TNF agents in the treatment of rheumatoid arthritis.由rhnews@elsevier.com (Rheumatology News International)
  continue reading
 
Professor VonVollenhoven discusses factors which distinguish individual responses by patients with rheumatoid arthritis to various anti-TNF agents. He describes observations of radiologic and clinical progression of illness in subgroups of patients and provides an overview of considerations in choosing one pharmacologic agent over another. Professo…
  continue reading
 
Contemporary research shows that the early diagnosis and treatment of RA can offer patients the possibility of achieving remission. The goal for any patient with early RA should be to achieve remission. If a patient does not already have joint damage, the goal should be a normal acute-phase response and no swollen joints as soon as possible.…
  continue reading
 
Professor Smolen discusses the evidence supporting the ability of TNF-alpha agents to result in substantial and sustained improvement in symptoms of psoriatic arthritis. Agents including infliximab and etanercept result in not only clinical improvement but also slow the radiographic progression of joint disease and damage. Further, the combination …
  continue reading
 
Professor Sir Ravinder Maini's groundbreaking work on the characterization of TNF-alpha began in the mid-1980's with his collaboration with Professor Mark Feldman. In his study of intercellular messenger molecules, Professor Sir Maini utilized two new technologies -- protein sequencing and cDNA protein coding -- to investigate half a dozen cytokine…
  continue reading
 
Loading …

快速参考指南